Prostate Cancer Registries: Current Status and Future Directions

European Urology

Volumn 69, Issue 6, 2016, Pages 998-1012

  Gandaglia, Giorgio ^a   Bray, Freddie ^b   Cooperberg, Matthew R ^c   Karnes, R Jeffrey ^d   Leveridge, Michael J ^e   Moretti, Kim ^f,g   Murphy, Declan G ^h   Penson, David F ⁱ   Miller, David C ^j  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e QUEEN S UNIVERSITY   (Canada)

^f Sleep Disorders Unit   (United States)

^g UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

ⁱ VANDERBILT UNIVERSITY   (United States)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

more..

Author keywords

Disease specific outcomes; Epidemiology; Population based; Prospective registries; Prostate cancer; Statistical approaches

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; EMBASE; EXTERNAL VALIDITY; FEEDBACK SYSTEM; HEALTH CARE PERSONNEL; HEALTH SERVICE; HUMAN; MALE; MEDLINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; WEB OF SCIENCE; AUSTRALIA; JAPAN; MEDICAL RECORD; NORWAY; PROSTATE TUMOR; REGISTER; SOUTH KOREA; STATISTICS; SWEDEN; UNITED STATES;

AUSTRALIA; HUMANS; JAPAN; MALE; MEDICAL RECORD LINKAGE; NORWAY; PROSTATIC NEOPLASMS; REGISTRIES; REPUBLIC OF KOREA; SEER PROGRAM; STATISTICS AS TOPIC; SWEDEN; UNITED STATES;

EID: 84930326701     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.05.046     Document Type: Article

References (139)

1. A. Heidenreich, P.J. Bastian, J. Bellmunt, and et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent: update 2013 Eur Urol 65 2014 124 137
2. P. Dahm, J. N'Dow, L. Holmberg, and F. Hamdy The future of randomised controlled trials in urology Eur Urol 66 2014 1 3
3. A.A. Hussein, C.J. Welty, J. Broering, M.R. Cooperberg, and P.R. Carroll National prostate cancer registries: contemporary trends of prostate cancer in the United States Urol Pract 1 2014 198 204
4. D. Su, and T.L. Jang Using large institutional or national databases to evaluate prostate cancer outcomes and patterns of care: possibilities and limitations Sci World J 11 2011 147 160
5. M.R. Cooperberg, J.M. Broering, M.S. Litwin, and et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry J Urol 171 2004 1393 1401
6. K.D. Stensland, R.B. McBride, A. Latif, and et al. Adult cancer clinical trials that fail to complete: an epidemic? J Natl Cancer Inst 106 2014 dju229
7. C.M. Booth, and I.F. Tannock Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence Br J Cancer 110 2014 551 555
8. J.H. Lewis, M.L. Kilgore, D.P. Goldman, and et al. Participation of patients 65 years of age or older in cancer clinical trials J Clin Oncol 21 2003 1383 1389
9. J.M. Unger, D.L. Hershman, K.S. Albain, and et al. Patient income level and cancer clinical trial participation J Clin Oncol 31 2013 536 542
10. L.F. Hutchins, J.M. Unger, J.J. Crowley, C.A. Coltman Jr., and K.S. Albain Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 1999 2061 2067
11. V.H. Murthy, H.M. Krumholz, and C.P. Gross Participation in cancer clinical trials: race-, sex-, and age-based disparities JAMA 291 2004 2720 2726
12. A. Kay, J. Higgins, A.G. Day, R.M. Meyer, and C.M. Booth Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points Ann Oncol 23 2012 1646 1651
13. C.M. Booth, D.W. Cescon, L. Wang, I.F. Tannock, and M.K. Krzyzanowska Evolution of the randomized controlled trial in oncology over three decades J Clin Oncol 26 2008 5458 5464
14. J. Peppercorn, E. Blood, E. Winer, and A. Partridge Association between pharmaceutical involvement and outcomes in breast cancer clinical trials Cancer 109 2007 1239 1246
15. D.A. Barocas, V. Chen, M. Cooperberg, and et al. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study J Comp Eff Res 2 2013 445 460
16. J. Concato, E.V. Lawler, R.A. Lew, J.M. Gaziano, M. Aslan, and G.D. Huang Observational methods in comparative effectiveness research Am J Med. 123 12 Suppl 1 2010 e16 e23
17. W. Yang, A. Zilov, P. Soewondo, O.M. Bech, F. Sekkal, and P.D. Home Observational studies: going beyond the boundaries of randomized controlled trials Diabetes Res Clin Pract 88 Suppl 1 2010 S3 S9
18. Q.D. Trinh, A. Bjartell, S.J. Freedland, and et al. A systematic review of the volume-outcome relationship for radical prostatectomy Eur Urol 64 2013 786 798
19. Q.D. Trinh, M. Sun, S.P. Kim, and et al. The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy Urol Oncol 32 2014 29 e13-20
20. A.J. Vickers, C.J. Savage, M. Hruza, and et al. The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study Lancet Oncol 10 2009 475 480
21. C. Jeldres, N. Suardi, F. Saad, and et al. High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer Eur Urol 54 2008 97 106
22. J. Olsen, O. Basso, and H.T. Sorensen What is a population-based registry? Scand J Public Health 27 1999 78
23. D.M. Parkin The evolution of the population-based cancer registry Nat Rev Cancer 6 2006 603 612
24. C. Navarro, C. Martos, E. Ardanaz, and et al. Population-based cancer registries in Spain and their role in cancer control Ann Oncol 21 Suppl 3 2010 iii3 iii13
25. D.F. Penson, and P.C. Albertsen Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom Surg Oncol 11 2002 3 11
26. E. Scosyrev, J. Messing, K. Noyes, P. Veazie, and E. Messing Surveillance Epidemiology and End Results (SEER) program and population-based research in urologic oncology: an overview Urol Oncol 30 2012 126 132
27. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
28. M. Van Hemelrijck, A. Wigertz, F. Sandin, and et al. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer Data Base Sweden 2.0 Int J Epidemiol 42 2013 956 967
29. H. Suleman A system for high quality crowdsourced indigenous language transcription Int J Digital Libr 14 3/4 2014 117 125
30. T. Wolters, M.J. Roobol, P.J. van Leeuwen, and et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial J Urol 185 2011 121 125
31. J.L. Warren, C.N. Klabunde, D. Schrag, P.B. Bach, and G.F. Riley Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population Med Care 40 8 Suppl 2002 IV-3-18
32. T. Matsuoka, K. Kawai, T. Kimura, and et al. Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer J Cancer Res Clin Oncol. 141 2015 759 765
33. National Cancer Institute. Overview of the SEER program. http://seer.cancer.gov/about/overview.html
34. C.P. Filson, F.R. Schroeck, Z. Ye, J.T. Wei, B.K. Hollenbeck, and D.C. Miller Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer J Urol 192 2014 75 80
35. M.J. Resnick, T. Koyama, K.H. Fan, and et al. Long-term functional outcomes after treatment for localized prostate cancer N Engl J Med 368 2013 436 445
36. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, L.L. Egevad ISUP Grading Committee The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242
37. R.M. Hoffman, T. Koyama, K.H. Fan, and et al. Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer J Natl Cancer Inst 105 2013 711 718
38. S.P. Porten, M.R. Cooperberg, B.R. Konety, and P.R. Carroll The example of CaPSURE: lessons learned from a national disease registry World J Urol 29 2011 265 271
39. J.E. Montie, S.M. Linsell, and D.C. Miller Quality of care in urology and the Michigan Urological Surgery Improvement Collaborative Urol Pract 1 2014 74 78
40. South Australian Prostate Cancer Clinical Outcome Collaborative. About the database. http://www.sa-pccoc.com/the-database
41. S.M. Evans, J.L. Millar, J.M. Wood, and et al. The prostate cancer registry: monitoring patterns and quality of care for men diagnosed with prostate cancer BJU Int 111 2013 E158 E166
42. S.M. Evans, J.L. Millar, I.D. Davis, and et al. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011 Med J Aust 198 2013 540 545
43. S.M. Evans, J.L. Millar, M. Frydenberg, and et al. Positive surgical margins: rate, contributing factors and impact on further treatment: findings from the prostate cancer registry BJU Int 114 2014 680 690
44. M. Weerakoon, N. Papa, N. Lawrentschuk, and et al. The current use of active surveillance in an Australian cohort of men: a pattern of care analysis from the Victorian prostate cancer registry BJU Int 115 Suppl 5 2015 50 56
45. D.H. Lee, S.H. Lee, K.H. Rha, and et al. The establishment of K-CaP (the multicenter Korean prostate cancer database) Korean J Urol 54 2013 229 233
46. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
47. M.M. Center, A. Jemal, J. Lortet-Tieulent, and et al. International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
48. M.R. Cooperberg, J.M. Broering, P.W. Kantoff, and P.R. Carroll Contemporary trends in low risk prostate cancer: risk assessment and treatment J Urol 178 2007 S14 S19
49. U. Mahmood, L.B. Levy, P.L. Nguyen, A.K. Lee, D.A. Kuban, and K.E. Hoffman Current clinical presentation and treatment of localized prostate cancer in the United States J Urol 192 2014 1650 1656
50. E. Scosyrev, E.M. Messing, S. Mohile, D. Golijanin, and G. Wu Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality Cancer 118 2012 3062 3070
51. C.D. Scales Jr., J.W. Moul, L.H. Curtis, and et al. Prostate cancer in the baby boomer generation: results from CaPSURE Urology 70 2007 1162 1167
52. R. Kvale, A. Auvinen, H.O. Adami, and et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries J Natl Cancer Inst 99 2007 1881 1887
53. D.M. Marcus, M. Goodman, A.B. Jani, A.O. Osunkoya, and P.J. Rossi A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008 Prostate Cancer Prostatic Dis 15 2012 283 288
54. K.A. Moses, A.T. Paciorek, D.F. Penson, P.R. Carroll, and V.A. Master Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE J Clin Oncol 28 2010 1069 1074
55. M.A. Dall'era, N. Hosang, B. Konety, J.E. Cowan, and P.R. Carroll Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease J Urol 181 2009 1622 1627
56. C.R. Ritch, A.J. Graves, K.A. Keegan, and et al. Increasing use of observation among men at low risk for prostate cancer mortality J Urol 193 2015 801 806
57. M.D. Tyson, P.E. Andrews, D.A. Etzioni, and et al. Marital status and prostate cancer outcomes Can J Urol 20 2013 6702 6706
58. B.A. Spencer, B.J. Insel, D.L. Hershman, M.C. Benson, and A.I. Neugut Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer Support Care Cancer 21 2013 1303 1311
59. D.M. Latini, E.P. Elkin, M.R. Cooperberg, N. Sadetsky, J. Duchane, and P.R. Carroll Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE Cancer 106 2006 789 795
60. D.R. Ziehr, B.A. Mahal, A.A. Aizer, and et al. Income inequality and treatment of African American men with high-risk prostate cancer Urol Oncol 33 2015 18.e7-13
61. C.J. Kane, D.P. Lubeck, S.J. Knight, and et al. Impact of patient educational level on treatment for patients with prostate cancer: data from CaPSURE Urology 62 2003 1035 1039
62. C.E. Pollack, J.E. Bekelman, A.J. Epstein, K. Liao, Y.N. Wong, and K. Armstrong Racial disparities in changing to a high-volume urologist among men with localized prostate cancer Med Care 49 2011 999 1006
63. M.H. Hayn, H. Orom, V.L. Shavers, and et al. Racial/ethnic differences in receipt of pelvic lymph node dissection among men with localized/regional prostate cancer Cancer 117 2011 4651 4658
64. W.R. Carpenter, D.L. Howard, Y.J. Taylor, L.E. Ross, S.E. Wobker, and P.A. Godley Racial differences in PSA screening interval and stage at diagnosis Cancer Causes Control 21 2010 1071 1080
65. M. Lycken, H. Garmo, J. Adolfsson, P. Stattin, L. Holmberg, and A. Bill-Axelson Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study Eur J Cancer 50 2014 1789 1798
66. P.R. Womble, J.E. Montie, Z. Ye, and et al. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer Eur Urol 67 2015 44 50
67. L.C. Harlan, A. Potosky, F.D. Gilliland, and et al. Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study J Natl Cancer Inst 93 2001 1864 1871
68. A.J. Vickers, D.D. Sjoberg, D. Ulmert, and et al. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen BMC Med 12 2014 26
69. J.C. Hu, S.B. Williams, S.C. Carter, and et al. Population-based assessment of prostate-specific antigen testing for prostate cancer in the elderly Urol Oncol 33 2015 69 e29-34
70. R. Kvale, B. Moller, A. Angelsen, and et al. Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980-2007 Cancer Epidemiol 34 2010 359 367
71. D.V. Makarov, R.A. Desai, J.B. Yu, and et al. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the Medicare population J Urol 187 2012 97 102
72. R.C. Chen, W.R. Carpenter, L.H. Hendrix, and et al. Receipt of guideline-concordant treatment in elderly prostate cancer patients Int J Radiat Oncol Biol Phys 88 2014 332 338
73. S.D. Ellis, B. Blackard, W.R. Carpenter, and et al. Receipt of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina Cancer 119 2013 2282 2290
74. F. Abdollah, A. Abdo, M. Sun, and et al. Pelvic lymph node dissection for prostate cancer: adherence and accuracy of the recent guidelines Int J Urol 20 2013 405 410
75. S.H. Javid, T.K. Varghese, A.M. Morris, and et al. Guideline-concordant cancer care and survival among American Indian/Alaskan Native patients Cancer 120 2014 2183 2190
76. L.M. Ellison, B.J. Trock, N.R. Poe, and A.W. Partin The effect of hospital volume on cancer control after radical prostatectomy J Urol 173 2005 2094 2098
77. F. Abdollah, M. Sun, R. Thuret, and et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006 Eur Urol 59 2011 88 95
78. G. Gandaglia, J.D. Sammon, S.L. Chang, and et al. Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era J Clin Oncol 32 2014 1419 1426
79. E.F. Crandley, S.E. Hegarty, T. Hyslop, D.D. Wilson, A.P. Dicker, and T.N. Showalter Treatment-related complications of radiation therapy after radical prostatectomy: comparative effectiveness of intensity-modulated versus conformal radiation therapy Cancer Med 3 2014 397 405
80. G. Gandaglia, F. Abdollah, J. Hu, and et al. Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments J Endourol 28 2014 784 791
81. S.M. Prasad, X. Gu, K.J. Kowalczyk, S.R. Lipsitz, P.L. Nguyen, and J.C. Hu Morbidity and costs of salvage vs. primary radical prostatectomy in older men Urol Oncol 31 2013 1477 1482
82. W.W. Choi, X. Gu, S.R. Lipsitz, A.V. D'Amico, S.B. Williams, and J.C. Hu The effect of minimally invasive and open radical prostatectomy surgeon volume Urol Oncol 30 2012 569 576
83. S.B. Williams, Y. Lei, P.L. Nguyen, and et al. Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer BJU Int 110 2012 E92 E98
84. J.E. Bekelman, N. Mitra, E.A. Handorf, and et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer J Clin Oncol 33 2015 716 722
85. J.D. Sammon, F. Abdollah, G. Reznor, and et al. Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer Eur Urol 68 2015 32 39
86. G. Gandaglia, P.I. Karakiewicz, A. Briganti, and et al. Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study Ann Oncol 25 2014 979 986
87. S.H. Culp, P.F. Schellhammer, and M.B. Williams Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study Eur Urol 65 2014 1058 1066
88. J. Xia, B.J. Trock, M.R. Cooperberg, and et al. Prostate cancer mortality following active surveillance versus immediate radical prostatectomy Clin Cancer Res 18 2012 5471 5478
89. M.R. Cooperberg, A.J. Vickers, J.M. Broering, and P.R. Carroll Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer Cancer. 116 2010 5226 5334
90. O. Akre, H. Garmo, J. Adolfsson, M. Lambe, O. Bratt, and P. Stattin Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden Eur Urol 60 2011 554 563
91. P. Sooriakumaran, T. Nyberg, O. Akre, and et al. Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes BMJ 348 2014 g1502
92. D. Margel, D.R. Urbach, L.L. Lipscombe, and et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes J Clin Oncol 31 2013 3069 3075
93. J.M. Degroot, M.D. Brundage, M. Lam, and et al. Prostate cancer-specific survival differences in patients treated by radical prostatectomy versus curative radiotherapy Can Urol Assoc J 7 2013 E299 E305
94. D.R. Withrow, J.M. DeGroot, D.R. Siemens, and P.A. Groome Therapeutic value of lymph node dissection at radical prostatectomy: a population-based case-cohort study BJU Int 108 2011 209 216
95. S. Punnen, J.E. Cowan, J.M. Chan, P.R. Carroll, and M.R. Cooperberg Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry Eur Urol 68 2015 600 608
96. L. Budaus, M. Bolla, A. Bossi, and et al. Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature Eur Urol 61 2012 112 127
97. V. Ficarra, G. Novara, R.C. Rosen, and et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy Eur Urol 62 2012 405 417
98. S.A. Boorjian, J.A. Eastham, M. Graefen, and et al. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes Eur Urol 61 2012 664 675
99. N.E. Martin, L. Massey, C. Stowell, and et al. Defining a standard set of patient-centered outcomes for men with localized prostate cancer Eur Urol 67 2015 460 467
100. M.K. Tollefson, M.T. Gettman, R.J. Karnes, and I. Frank Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy J Urol 185 2011 1686 1690
101. G. Gandaglia, and Q.D. Trinh Models of assessment of comparative outcomes of robot-assisted surgery: best evidence regarding the superiority or inferiority of robot-assisted radical prostatectomy Urol Clin North Am 41 2014 597 606
102. A.A. Aizer, X. Gu, M.H. Chen, and et al. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States J Natl Compr Canc Netw 13 2015 61 68
103. P.L. Nguyen, X. Gu, S.R. Lipsitz, and et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer J Clin Oncol 29 2011 1517 1524
104. X. Ma, R. Wang, J.B. Long, and et al. The cost implications of prostate cancer screening in the Medicare population Cancer 120 2014 96 102
105. M.D. Krahn, K.E. Bremner, J. Luo, and S.M. Alibhai Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events Curr Oncol 21 2014 e457 e465
106. L.S. Wilson, R. Tesoro, E.P. Elkin, and et al. Cumulative cost pattern comparison of prostate cancer treatments Cancer 109 2007 518 527
107. M.R. Cooperberg Progress in management of low-risk prostate cancer: how registries may change the world Eur Urol 67 2015 51 52
108. F.R. Schroeck, S.R. Kaufman, B.L. Jacobs, and B.K. Hollenbeck Receipt of best care according to current quality of care measures and outcomes in men with prostate cancer J Urol 193 2015 500 506
109. F.R. Schroeck, S.R. Kaufman, B.L. Jacobs, and et al. Regional variation in quality of prostate cancer care J Urol 191 2014 957 962
110. R. Jayadevappa, S. Chhatre, J.C. Johnson, and S.B. Malkowicz Variation in quality of care among older men with localized prostate cancer Cancer 117 2011 2520 2529
111. S.H. Giordano, Y.F. Kuo, Z. Duan, G.N. Hortobagyi, J. Freeman, and J.S. Goodwin Limits of observational data in determining outcomes from cancer therapy Cancer 112 2008 2456 2466
112. B. Delahunt, R.J. Miller, J.R. Srigley, A.J. Evans, and H. Samaratunga Gleason grading: past, present and future Histopathology 60 2012 75 86
113. R.B. D'Agostino Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
114. J.M. Brooks, and R.L. Ohsfeldt Squeezing the balloon: propensity scores and unmeasured covariate balance Health Serv Res 48 2013 1487 1507
115. J. Hadley, K.R. Yabroff, M.J. Barrett, D.F. Penson, C.S. Saigal, and A.L. Potosky Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data J Natl Cancer Inst 102 2010 1780 1793
116. E.L. Korn, and B. Freidlin Methodology for comparative effectiveness research: potential and limitations J Clin Oncol 30 2012 4185 4187
117. J.A. Rassen, M.A. Brookhart, R.J. Glynn, M.A. Mittleman, and S. Schneeweiss Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships J Clin Epidemiol 62 2009 1226 1232
118. M.J. Englesbe, J.B. Dimick, C.J. Sonnenday, D.A. Share, and D.A. Campbell Jr. The Michigan surgical quality collaborative: will a statewide quality improvement initiative pay for itself? Ann Surg 246 2007 1100 1103
119. G.L. Lu-Yao, P.C. Albertsen, D.F. Moore, and et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer JAMA 300 2008 173 181
120. G. Gandaglia, M. Sun, J.C. Hu, and et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer Eur Urol 66 2014 1125 1132
121. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
122. B.L. Jacobs, Y. Zhang, F.R. Schroeck, and et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer JAMA 309 2013 2587 2595
123. M.J. Resnick, D.A. Barocas, A.K. Morgans, and et al. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: defining the population at risk for harms of prostate cancer treatment Cancer 120 2014 1263 1271
124. M.J. Resnick, D.A. Barocas, A.K. Morgans, and et al. The evolution of self-reported urinary and sexual dysfunction over the last two decades: implications for comparative effectiveness research Eur Urol 67 2015 1019 1025
125. A. Bill-Axelson, H. Garmo, U. Nyberg, and et al. Psychiatric treatment in men with prostate cancer - results from a Nation-wide, population-based cohort study from PCBaSe Sweden Eur J Cancer 47 2011 2195 2201
126. D. Robinson, H. Garmo, B. Lindahl, and et al. Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden Int J Cancer 130 2012 478 487
127. E. Hernes, A. Kyrdalen, R. Kvale, and et al. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry BJU Int 105 2010 805 811
128. S.D. Fossa, Y. Nilssen, R. Kvale, E. Hernes, K. Axcrona, and B. Moller Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience Urology 83 2014 146 152
129. M.R. Cooperberg, D.J. Pasta, E.P. Elkin, and et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938 1942
130. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
131. K.C. Cary, N. Singla, J.E. Cowan, P.R. Carroll, and M.R. Cooperberg Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE registry J Urol 191 2014 964 970
132. M. Jalloh, F. Myers, J.E. Cowan, P.R. Carroll, and M.R. Cooperberg Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics Eur Urol 67 2015 451 457
133. D.C. Miller, D.S. Murtagh, R.S. Suh, and et al. Regional collaboration to improve radiographic staging practices among men with early stage prostate cancer J Urol 186 2011 844 849
134. P.R. Womble, M.W. Dixon, S.M. Linsell, and et al. Infection related hospitalizations after prostate biopsy in a statewide quality improvement collaborative J Urol 191 2014 1787 1792
135. C.P. Filson, B. Boer, J. Curry, and et al. Improvement in clinical TNM staging documentation within a prostate cancer quality improvement collaborative Urology 83 2014 781 786
136. Z. Shi, C.B. Pinnock, S. Kinsey-Trotman, and et al. Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death Radiother Oncol 107 2013 129 133
137. D.J. Tamblyn, S. Chopra, C. Yu, M.W. Kattan, C. Pinnock, and T. Kopsaftis Comparative analysis of three risk assessment tools in Australian patients with prostate cancer BJU Int 108 Suppl 2 2011 51 56
138. K. Tomic, F. Sandin, A. Wigertz, D. Robinson, M. Lambe, and P. Stattin Evaluation of data quality in the National Prostate Cancer Register of Sweden Eur J Cancer. 51 2015 101 111
139. NPCR, http://www.npcr.se, accessed 18 June 2015.